Vanda Pharmaceuticals (NASDAQ:VNDA) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $20.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com began coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating for the company.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ VNDA opened at $3.96 on Wednesday. The company has a market cap of $233.38 million, a P/E ratio of -12.38 and a beta of 0.69. The firm’s fifty day moving average is $4.52 and its two-hundred day moving average is $4.65. Vanda Pharmaceuticals has a 52-week low of $3.85 and a 52-week high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The company had revenue of $50.04 million for the quarter, compared to the consensus estimate of $45.13 million. As a group, analysts forecast that Vanda Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Insider Activity

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the firm’s stock in a transaction dated Friday, February 28th. The stock was purchased at an average price of $4.76 per share, for a total transaction of $47,600.00. Following the acquisition, the chief executive officer now owns 2,361,730 shares in the company, valued at approximately $11,241,834.80. This trade represents a 0.43 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders acquired 32,000 shares of company stock worth $151,180. 8.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Barclays PLC boosted its position in Vanda Pharmaceuticals by 128.2% in the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock valued at $722,000 after buying an additional 86,677 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Vanda Pharmaceuticals by 16.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 160,722 shares of the biopharmaceutical company’s stock valued at $754,000 after acquiring an additional 22,249 shares during the last quarter. SG Americas Securities LLC lifted its position in Vanda Pharmaceuticals by 26.8% during the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 5,459 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Vanda Pharmaceuticals by 4.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company’s stock valued at $3,925,000 after buying an additional 38,449 shares during the last quarter. Finally, Monaco Asset Management SAM boosted its stake in shares of Vanda Pharmaceuticals by 92.8% in the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company’s stock worth $1,879,000 after buying an additional 188,836 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.